Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study to Assess the Safety and Tolerability of Monthly Subcutaneous Administrations of a Low and High Dose Cohort of Osocimab to ESRD Patients on Regular Hemodialysis

NCT04523220 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04523220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04523220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study to Assess the Safety and Tolerability of Monthly Subcutaneous Administrations of a Low and High Dose Cohort of Osocimab to ESRD Patients on Regular Hemodialysis
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2020
Completion date
May 30, 2022
Enrollment
704 (actual)
Sites
151

Conditions

As the registry lists them; a condition with its own page is linked.

end-stage renal disease, hemodiafiltration, hemodialysis, prevention of thromboembolic events